Alberto Ocaña-rekin lankidetzan egindako argitalpenak (3)

2018

  1. Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

    European Journal of Cancer, Vol. 94, pp. 199-205

2017

  1. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

    Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153

2013

  1. The evolving landscape of protein kinases in breast cancer: Clinical implications

    Cancer Treatment Reviews, Vol. 39, Núm. 1, pp. 68-76